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Activation of NF-E2-related factor 2 (Nrf2) is a potential therapeutic intervention against endothelial cell oxidative stress
and associated vascular disease. We hypothesized that treatment with the phytochemicals in the patented dietary supplement
Protandim would induce Nrf2 nuclear localization and phase II antioxidant enzyme protein in human coronary artery endothelial
cells (HCAECs), protecting against an oxidant challenge in an Nrf2- dependent manner. Protandim treatment induced Nrf2
nuclear localization, and HO-1 (778% of control ± 82.25 P<0.01), SOD1 (125.9% of control ± 6.05 P<0.01), NQO1 (126%
of control ± 6.5 P<0.01), and GR (119.5% of control ± 7.00 P<0.05) protein expression in HCAEC. Treatment of HCAEC
with H2O2 induced apoptosis in 34% of cells while pretreatment with Protandim resulted in only 6% apoptotic cells (P<0.01).
Nrf2silencingsigniﬁcantlydecreased theProtandim-inducedincreaseinHO-1protein(P<0.01). Nrf2silencingalso signiﬁcantly
decreased the protection aﬀorded by Protandim against H2O2- induced apoptosis (P<0.01 compared to no RNA, and P<0.05
compared to control RNA). These results show that Protandim induces Nrf2 nuclear localization and antioxidant enzyme
expression, and protection of HCAEC from an oxidative challenge is Nrf2 dependent.
1.Introduction
Oxidative stress has been implicated in many chronic dis-
eases including Alzheimer’s, diabetes and coronary artery
disease (CAD) [1–4]. Increased production of reactive oxy-
gen species (ROS) and oxidative damage in the vascular
endothelium contribute to CAD initiation and progression.
Speciﬁcally, increased vascular superoxide causes oxida-
tion of lipids, decreased nitric oxide availability, increased
expression of adhesion molecules and inﬂammatory medi-
ators, and recruitment of monocytes to the endothelium
[5–8]. Endothelium-bound superoxide dismutase is also
decreased in CAD patients compared to healthy controls,
impairing the cellular response to excessive ROS produc-
tion [9]. Atherosclerotic coronary arteries isolated from
humans display increased superoxide production compared
to nonatherosclerotic human coronary arteries, and in a
mouse model of atherosclerosis, attenuation of superoxide
production by decreased expression of NADPH oxidase
(NOX) results in a decrease in atherosclerotic lesion size [10,
11].
Initial studies examining the eﬀects of decreasing oxida-
tive stress in several diseases, including cardiovascular dis-
ease, have used exogenous antioxidant supplements such
as vitamins C and E. However, the protective eﬀect of ex-
ogenous antioxidants has been disappointing and in some
cases supplementation increased mortality [12–14]. A novel
approach to decreasing disease-associated oxidative stress
involves augmenting endogenous antioxidant defense sys-
tems rather than relying on exogenous antioxidant supple-
mentation. Protandim is a commercially available dietary
supplement consisting of phytochemicals derived from ﬁve2 Oxidative Medicine and Cellular Longevity
widely studied medicinal plants including silymarin from
milk thistle, curcumin from turmeric, bacopa extract, ash-
wagandha, and green tea extract. The ﬁve phytochemical
components of Protandim have a synergistic eﬀect to induce
phaseIIantioxidantenzymesandprotectcellsfromoxidative
stress through activation of the transcription factor NF-E2-
related factor 2 (Nrf2) [15, 16].
Nrf2 is constitutively expressed but is marked for ubiqui-
tination by association with Kelch-like ECH-associated pro-
tein 1 (Keap1) in the cytosol. Activation of Nrf2 occurs when
it is released from Keap1 and translocates to the nucleus.
In the nucleus, Nrf2 heterodimerizes with small Maf or
Jun proteins and binds to the antioxidant response element
(ARE) in the promoter region of several hundred genes
including many phase II antioxidant enzymes subsequently
initiating transcription [17, 18]. Protandim likely activates
Nrf2 through activation of various kinases with subsequent
Nrf2 phosphorylation [16, 19].
Although acute activation of Nrf2 occurs in vivo in
response to oxidized phospholipid signaling, increased ROS
production, hyperglycemia, and shear stress [20–22], in
chronic disease states the antioxidant response is often
insuﬃcient to maintain redox balance and prevent disease
progression [22–24]. For example, Landmesser et al. report
increased SOD activity in young hypercholesterolemic sub-
jects compared to age-matched controls [9]. In contrast,
decreased SOD activity was observed in coronary arteries
from CAD patients compared to age-matched controls [9].
DatashowthatupregulationofphaseIIantioxidant enzymes
can protect against oxidative stress in vitro and in humans
[16, 25, 26]. It was also recently reported that Protandim
protected a human saphenous vein ex vivo culture from
oxidative stress-induced hyperplasia and vessel wall thick-
ening [27]. Thus, phytochemical-induced Nrf2 activation
is a potential therapeutic intervention against endothelial
cell oxidative stress and associated vascular disease initiation
and progression. Limited research (8 publications) exists
examining whether Protandim treatment can minimize the
pathologies associated with chronic diseases. The eﬀects of
Protandim on Nrf2 and oxidative stress in human coronary
vascular cells have not been investigated.
The purpose of this study was to determine (1) if treat-
ment with Protandim-induces Nrf2 nuclear translocation
and phase II antioxidant enzyme protein expression in
human coronary artery endothelial cells (HCAEC), (2) if
treatment with Protandim protects HCAEC from apoptosis
induced by an oxidant challenge, and (3) if Nrf2 mediates
Protandim induced protection from an oxidative challenge.
We hypothesized that Protandim treatment would induce
Nrf2 nuclear localization and phase II antioxidant enzyme
protein expression, and Protandim treatment prior to an
oxidant challenge would aﬀord cells protection in a Nrf2
dependent manner.
2.MaterialsandMethods
2.1. Materials. HCAEC and cell culture reagents, Prime-
Fect siRNA transfection reagent and PrimeFect diluent
were purchased from Lonza (Walkersville, MD). Heme
oxygenase-1 (HO-1) antibody was from Aﬃnity Bioreagents
(Golden, CO), nitroquinone oxidoreductase (NQO1), and
glutathione reductase (GR) antibodies, and appropriate
HRP-conjugated secondary antibodies were purchased from
AbCam, (Cambridge, MA). Nrf2, Cu-Zn superoxide dis-
mutase (SOD1), and actin antibodies, HRP- and FITC-
conjugated appropriate secondary antibodies, and Nrf2
siRNA, and control RNA were purchased from Santa Cruz
Biotech (Santa Cruz, CA). The Santa Cruz Nrf2 siRNA
is a pool of 3 19–25 nt siRNA duplexes. Sequence one
5  to 3  sense: GCAUGCUACGUGAUGAGAtt, antisense:
UCUUCAUCACGUAGCAUGCtt, sequence two 5  to 3 
sense: CUCCUACUGUGAUGUGAAAtt, antisense: UUU-
CACAUCACAGUAGGAGtt, sequence three 5  to 3  sense:
GUGUCAGUAUGUUGAAUCtt, antisense: UGAUUCAA-
CAUACUGACACtt. The Pierce BCA assay kit for deter-
mining protein concentrations, protease and phosphatase
inhibitors, and SuperSignal West Dura substrate were from
Thermo Scientiﬁc (Rockford, IL). TUNEL assay kits were
from Roche (Indianapolis, IN).
2.2. Culture of HCAEC. Primary HCAECs were grown in
endothelialcellgrowthmedium(EBM-2)containing5%FBS
and manufacturer-recommended supplemental growth fac-
tors, antibiotics, and antimycotics. All assays were performed
on cells at 80–100% conﬂuence, between passages 3 and 12,
and were repeated at least 3 times in duplicate or triplicate.
2.3. Protandim and H2O2 Preparation and Treatment. Pro-
tandim is a phytochemical composition containing W. som-
nifera,B.monniera(45%bacosides),S.marianum,Ca.sinesis
(98% polyphenols and 45% (−)-epigallocatechin-3-gallate),
andcurcumin(95%)fromturmeric(Cu.longa)(LifeV antage
Corp., Salt Lake City, UT). Protandim extract was prepared
by mixing 500mg Protandim in 5mL 95% ethanol. The
mixture was rocked overnight at room temperature and then
centrifugedfor15minat3,000×g.Theresultingsupernatant
contains ethanol extracted Protandim at a concentration of
100mg/mL. The Protandim extract was diluted to 20μg/mL
with complete cell culture medium for all treatments follow-
ing initial concentration response experiments that showed
20μg/mL was the lowest concentration that signiﬁcantly
stimulated phase II antioxidant enzyme protein expression.
Cells not treated with Protandim were treated with 95%
ethanol as a vehicle control, with a maximum ethanol
concentration in the growth medium of 0.02% (2μLi n
10mL). H2O2 (30% W/W) was diluted in complete cell
growth medium to a ﬁnal concentration of 1.25μMf o ra l l
treatments. Protandim treatments ranged from 1hr to 12hrs
as indicated, and H2O2 treatments were 4hrs.
2.4. Western Blot Analyses. HCAEC were seeded in 65mm
polystyrene cell culture dishes and grown to at least 80%
conﬂuence prior to Protandim treatment. Following treat-
ment, cells were scraped in RIPA buﬀer (50mM Tris, 0.15M
NaCl, 1% Na deoxycholic acid, 1mM EGTA, 1% NP40) con-
taining protease and phosphatase inhibitors and sonicatedOxidative Medicine and Cellular Longevity 3
3 × 10secs. Protein concentrations were determined using a
BCA assay, and samples were diluted with Laemmli sample
buﬀer. Samples were separated on 10% polyacrylamide
gels at 125v and transferred to nitrocellulose membranes
(BioRad, Hercules, CA) for 1hr at 50v. Membranes were
blocked for 1hr in Superblock (Thermo Scientiﬁc, Rockford,
IL) then incubated with primary antibodies against HO-
1 (1:500), SOD1 (1:500), NQO1 (1:1000), GR (1:5000),
and β-actin (1:1000) followed by the appropriate HRP-
conjugated secondary antibodies. Membranes were devel-
oped by chemiluminescence using SuperSignal West Dura
substrate (Thermo Scientiﬁc, Rockford, IL), with digital
images obtained using the Biospectrum UVP system. All
signals were normalized to β-actin obtained from the same
blot and expressed as the percent of the vehicle control (no
Protandim) condition.
2.5. Immunocytochemistry for Nrf2 Nuclear Localization.
HCAECs were grown to conﬂuence on coverslips in
35mm polystyrene cell culture plates coated with 2μg/cm2
ﬁbronectin prior to Protandim treatment. Cells were initially
treated with Protandim for 1hr, 2hrs, 4hrs, 8hrs, and
12hrs to determine the optimal duration of treatment for
visualizing Nrf2 nuclear localization. Following time course
experiments, all Protandim treatments were for 1hr. Cells
were washed with PBS, ﬁxed for 30min in 4% paraformalde-
hyde, washed with PBS, and then permeabilized in cold
acetone for 30min. Cells were blocked for 1hr in 5% bovine
serum albumin with 0.5% goat serum and then incubated
with Nrf2 primary antibody (1:100) for 1hr at room
temperature. Cells were washed with PBS then incubated
for 45min in FITC-conjugated secondary antibody at room
temperature in the dark. The coverslips were mounted
on slides using DAPI containing mounting medium for
identiﬁcation of cell nuclei and visualized by ﬂuorescence
microscopy (Nikon TE2000) using Metamorph data acqui-
sition software (Molecular Devices, Sunnyvale, CA).
2.6. TUNEL Assay to Assess Apoptosis. A TdT-mediated
dUTP nick end labeling (TUNEL) assay was used to assess
HCAEC apoptosis in response to an oxidative challenge.
Cells were grown to conﬂuence on ﬁbronectin-coated cov-
erslips prior to Protandim and H2O2 treatment. Cells were
washed with PBS, ﬁxed for 30min in 4% paraformaldehyde,
washed again with PBS, then permeabilized for 2min in
0.1% Triton X-100 with 0.1% sodium citrate. Cells were
washed again with PBS and incubated in TUNEL reagent
for 1.5hrs. The coverslips were then mounted on slides
using DAPI containing mounting medium to identify cell
nuclei.Signalswerevisualizedusingﬂuorescencemicroscopy
(Nikon TE2000).
2.7. Nrf2 Silencing. Prior to transfection, 250μLP r i m e F e c t
diluent was mixed with 5μL PrimeFect transfection reagent
and incubated at room temperature for 15min. Nrf2 siRNA
or control RNA was added to the transfection solution
for a ﬁnal concentration of 50nM and incubated at room
temperature for 15min. The transfection solution was
applied to cells grown to 70–80% conﬂuence in antibiotic
free medium, along with 1.25mL antibiotic free growth
medium. The volume of transfection reagent used caused
minimal distress to the cells as assessed by minimal changes
to cell morphology. After 24hrs, the transfection solution
was removed and the cells were rinsed with PBS, treated with
Protandim, and assayed as indicated.
2.8. Statistical Analysis. Unpaired t-tests were used to com-
pare control versus Protandim treatments. A two by three
treatment (Protandim and no Protandim) by condition (no
RNA, control RNA, and Nrf2 siRNA) ANOVA with ap r i o r i
linear contrasts of means was used to analyze Nrf2 silencing
experiments. Percent protection was analyzed using one-way
ANOVA. Statistical signiﬁcance was set at P<0.05.
3. Results
3.1. Antioxidant Enzyme Protein Expression Is Elevated in
Response to Protandim Treatment. HCAEC were treated with
Protandim concentrations of 0 to 50μg/mL in 5μg/mL
increments to determine a proﬁle of Nrf2 activation as
measuredbyHO-1proteincontent.HO-1proteinwentfrom
barelydetectableincontrolconditionsto8–10-foldgreaterin
cellstreatedwith20–30μg/mL(Figure 1(a)).Concentrations
higher than 30μg/mL induced morphological changes. In
all subsequent treatments 20μg/mL Protandim was used.
HO-1 protein was visible after 1hr of Protandim treatment
and became signiﬁcant and sustained from 4hrs through
the longest treatment period of 12hrs (data not shown).
To conﬁrm treatment concentration and duration on mul-
tiple antioxidant enzymes we determined that 20μg/mL
Protandim for 12hrs induced HO-1 (778% of control +
82.25 P<0.01), SOD1 (125.9% of control + 6.05 P<0.01),
NQO1 (126% of control + 6.5 P<0.01), and GR (119.5%
of control + 7.00 P<0.05) (Figure 1(b)). All subsequent
treatments used Protandim at a concentration of 20μg/mL
for 12hrs unless otherwise noted.
3.2. Protandim Stimulates Nrf2 Nuclear Localization.
HCAECs were treated with Protandim for up to 12hrs
and subsequently visualized using immunocytochemistry
to determine Nrf2 nuclear localization. Nrf2 content and
nuclear localization were elevated as soon as 1hr after
Protandim treatment initiation. Induction remained with
treatments of 2, 4, 8, and 12hrs (12hrs was the longest
treatment duration examined) (Figure 2).
3.3. Protandim Protects HCAEC from Oxidative Challenge
Induced Apoptosis. HCAECs were treated for 12hrs with
Protandim or vehicle control followed by a 4hr exposure
to 1.25μMH 2O2 and induction of apoptosis was measured
by TUNEL assay. Protandim was removed prior to H2O2,
exposure. In vehicle controls apoptosis was induced in 34%
of cells (Figures 3(a) and 3(b)) while only 6% of cells treated4 Oxidative Medicine and Cellular Longevity
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Figure 1: Protandim treatment induces phase II antioxidant enzyme protein expression in HCAEC. (a) HCAECs were treated with 1–
50μg/mL of Protandim for 12hrs prior to measuring HO-1 protein expression. The HO-1 signal was veriﬁed using a puriﬁed HO-1 protein
extract positive control. (b) Following determination of the appropriate concentration of Protandim, HCAECs were treated with 20μg/mL
Protandim for 12hrs then protein expression of HO-1, GR, SOD-1, and NQO1 was determined by Western blot. All bands were normalized
to β-actin as a loading control and expressed as a percent of the control (vehicle) condition (n = 16 treatments). ∗P<0.01 compared
to control (no Protandim), ∗∗P<0.05 compared to control (no Protandim). Data are presented as mean + SE. Ptd: Protandim, Ctr: No
Protandim, + Ctr: HO-1 positive control.
with Protandim prior to H2O2 were apoptotic (P<0.01
compared to vehicle control) (Figures 3(a) and 3(b)).
3.4. Nrf2 Silencing Diminishes Protandim-Induced Increases
in HO-1 and Protection from an Oxidative Challenge. Nrf2
was silenced using siRNA prior to Protandim treatment to
determine if Protandim induced increases in antioxidant
enzyme expression and protection occur through Nrf2
activation. Nrf2 silencing prior to Protandim treatment
signiﬁcantly inhibited (P<0.01) Protandim-induced HO-1
protein expression compared to both the no RNA condition,
and control RNA condition. (Figures 4(a) and 4(b)). ThereOxidative Medicine and Cellular Longevity 5
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Figure 2: Protandim induced Nrf2 expression and nuclear localization. HCAECs were treated with Protandim for 1hr, following which
immunoﬂuorescence was used to visualize changes in Nrf2 expression and localization. Following Protandim treatment Nrf2 signal was
greater and became visible in the nucleus. Ptd: Protandim, Ctr: no Protandim.
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Figure 3: Protandim treatment protects HCAEC against an oxidative stress. HCAEC were treated with Protandim for 12hrs, followed
by H2O2 4hrs. (a) Treatment of HCAEC with Protandim prior to an oxidative challenge resulted in signiﬁcantly fewer apoptotic nuclei
as determined by TUNEL assay. (b) Approximately 35% of cells underwent apoptosis without Protandim treatment prior to an oxidative
challenge while pre-treatment with Protandim resulted in approximately 5% of cells undergoing apoptosis in response to the same oxidative
challenge (n = 18 ﬁelds) ∗P<0.01 compared to control (no Protandim). Data are presented as mean + SE percent of TUNEL positive (+)
nuclei. Ptd: Protandim, Ctr: no Protandim.
were no diﬀerences between no RNA and control RNA
conditions with or without Protandim.
Nrf2 was then silenced prior to Protandim treatment
and an oxidative challenge. In cells receiving no RNA and
cells that received control RNA, 30–40% of cells underwent
apoptosis(Figures5(a)and5(b).Nrf2siRNAtreatmentprior
to H2O2 resulted in apoptosis in 80% of cells (P<0.0001)
compared to no RNA conditions and control RNA (Figures
5(a)and5(b)).InbothnoRNAandcontrolRNAconditions,
Protandim treatment prior to H2O2 resulted in signiﬁcantly
fewerapoptoticcells(P<0.0001)(Figure 5(b)).Thenumber
of apoptotic cells in the no RNA condition compared to the
control RNA condition was not signiﬁcantly diﬀerent with
or without Protandim (P = 0.413 no Protandim, P = 0.093
withProtandim).ProtandimpriortoNrf2siRNAalsosignif-
icantly protected cells from apoptosis (P = 0.023); however
the amount of protection aﬀorded by the Protandim in this
condition was signiﬁcantly less than in no RNA and control
RNA conditions (P<0.01 and P<0.05, resp.) (Figure 5(c)).
4. Discussion
The novel ﬁndings of this study were that Protandim treat-
ment of HCAEC induced Nrf2 nuclear localization and
phase II antioxidant enzyme expression, Protandim treat-
ment prior to an oxidative challenge was protective against
apoptosis, and this protection was dependent on Nrf2. Our
data show that the phytochemical components of Protandim
increase Nrf2 in the cytosol and nucleus of HCAEC within
an hour of treatment. In cardiac myocytes we have observed
increases in Nrf2 within 15 minutes of Protandim treat-
ment (unpublished data). Nrf2 remains elevated through
treatment durations up to 12 hours, which was the longest
duration examined. These data show for the ﬁrst time an
immediate, substantial, and sustained eﬀect of Protandim on
Nrf2 in HCAEC.
4.1. Protandim Induction of Antioxidant Enzymes. The com-
ponents in Protandim work synergistically to activate Nrf2
and induce antioxidant enzyme expression. HO-1 mRNA
was increased to 500 percent of control in response to
40μg/mL Protandim in MIN6 cells and 1,000 percent of
control in response to 20μg/mL Protandim in SK-N-MC
cells [16]. However, when each phytochemical component of
Protandim was tested individually at the low concentration
found in Protandim extract, the maximum increase in
HO-1 mRNA was less than 200% of control [16]. While
we observed signiﬁcant increases in protein expression of6 Oxidative Medicine and Cellular Longevity
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Figure 4:SilencingofNrf2abrogatedProtandim-inducedincreasesinHO-1expression.(a)CellsweretreatedwithnoRNA,controlRNA,or
Nrf2siRNApriorto12hrsProtandim,thenHO-1expressiondeterminedbyWesternblotting.(b)HO-1expressioninresponsetoProtandim
treatment was elevated over 1,000% of control in the no RNA and control RNA conditions, while increases in HO-1 expression in the Nrf2
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multiple antioxidant enzymes (approximately 125% of con-
trol for SOD1, GR, and NQO1), the Protandim-induced
increase in HO-1 was over 700% of control. Until recently,
the antioxidant properties of HO-1 were thought to be
through production of the ROS scavenger bilirubin, but data
now suggest HO-1 may have other antioxidant qualities and
be important in multiple cell types in the vasculature. Kadl
et al. found that cell death in macrophages was exacerbated
in the absence of Nrf2 or with inhibition of HO-1 activity
[21].IthasalsobeendemonstratedinmacrophagesthatHO-
1 functions asan antioxidant by decreasing heme availability,
which decreases expression of the NADPH oxidase heme
containing subunit gp91phox and subsequently decreases
superoxide production [28].
Decreasing NOX superoxide production has important
implications in both macrophages and endothelial cells.
SubstantialevidenceexistsdemonstratingaroleforNOXand
increasedsuperoxideproductioninobesityandatherosclero-
sis. Compared to nonobese controls, overweight, and obese
subjects demonstrate increased NOX subunit expression and
augmented oxidative stress in the vascular endothelium [29].
NOX subunit expression is elevated in lesions of coronary
arteries in bypass graft patients, particularly in the vicinity
of macrophages, and NOX expression levels correlate with
severity of atherosclerosis [10]. Superoxide produced by any
mechanism including NOX is rapidly converted to H2O2.
Our experiments used H2O2 as an oxidative stress to induce
apoptosis in HCAEC. While the concentration of H2O2 used
inourexperimentswaschosenbasedonconsistentinduction
of apoptosis in 30–50% of untreated cells, H2O2 is a relevant
oxidant in vivo [30].
Whether HO-1 also functions as a protective antioxidant
in endothelial cells through decreasing heme availability,
inhibiting NOX, and decreasing superoxide production, or
via an alternative mechanism also is yet to be determined.
Greater baseline HO-1 expression in aortic endothelial cells
also results in decreased eﬀects of oxidized phospholipids on
inﬂammatory genes [31], suggesting that presence of HO-1
may delay progression of disease-related phenotypic changes
when cells are faced with chronic lipid and oxidative stresses.
While it was beyond the scope of this study, determining
whether HO-1 is essential to the Nrf2-dependent Protandim
induced protection against an oxidative challenge is war-
ranted.
SOD1, GR, and NQO1 were also signiﬁcantly elevated
in HCAEC in response to Protandim though the eﬀect was
not as large as that seen with HO-1. These are the ﬁrst
data indicating increases in GR and NQO1 in response to
Protandim; increases in SOD1 expression and activity have
been previously reported [15, 27]. In erythrocytes isolated
from human subjects following 120 days of Protandim
supplementation, SOD activity was increased by 30% [15].
In an ex vivo preparation of human saphenous veins,
Protandim treatment increased SOD activity 3-fold, HO-1
activity 7-fold, and catalase activity 12-fold [27]. Catalase
has been shown to be increased by Protandim and to
mediate protective eﬀects in erythrocytes and saphenous
vein preparations, as well as protect against skin cancer
development in an animal model [15, 27, 32]. Collectively,
these data suggest that the antioxidant enzymes increase
followingProtandimtreatmentinacelltypespeciﬁcmanner.Oxidative Medicine and Cellular Longevity 7
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Figure 5: Protandim treatment following Nrf2 silencing protected HCAEC against an oxidative challenge; however, protection following
Nrf2 silencing was signiﬁcantly diminished compared to controls. (a) Silencing of Nrf2 resulted in a signiﬁcant increase in the number
of cells undergoing apoptosis in response to an oxidative challenge regardless of Protandim. (b) In no RNA, control RNA, and Nrf2 RNA
conditions, signiﬁcantly fewer cells underwent apoptosis when treated with Protandim prior to an oxidative stress. The no RNA condition
and control RNA were not signiﬁcantly diﬀerent from each other with or without Protandim. In Nrf2 siRNA conditions, % TUNEL-positive
(+) nuclei were signiﬁcantly higher than no RNA and control RNA conditions with and without Protandim- (n = 15–19 ﬁelds) (c) The
percent protection by Protandim was not signiﬁcantly diﬀerent between no RNA and control RNA conditions. The protection aﬀorded by
Protandim in the Nrf2 siRNA condition was signiﬁcantly less compared to both no RNA and control RNA conditions. Data are presented
as means + SE. ∗P<0.01 between indicated groups, ∗∗P<0.05 between indicated groups. #P<0.01 compared to within RNA condition
control (no Protandim), ##P<0.05 compared to within RNA condition control (no Protandim). Ptd: Protandim, Ctr: No Protandim.
4.2. Nrf2 Mediated Protection against an Oxidative Challenge
byProtandim. ProtandimtreatmentprotectedHCAECfrom
H2O2-induced apoptosis, an eﬀect that was signiﬁcantly
diminished but not abrogated with silencing of Nrf2 prior to
Protandim treatment. There are multiple potential explana-
tions for this observation. First, diminished but incomplete
protection may be due to the rapid turnover rate in Nrf2.
Nrf2 is constitutively expressed and rapidly degraded. In
unstimulated cellsthe half-lifeof Nrf2 is less than 30 minutes
[33]. The delivered Nrf2 siRNA may be diminished prior to
the completion of Protandim and H2O2 treatments as Nrf2
is rapidly turned over. Second, the amount of siRNA that can
be delivered is limited by the ability of the cells to tolerate the
transfection procedure. The capacity of the delivered Nrf2
siRNA to silence Nrf2 may be exceeded by the previously
noted continuous turnover and subsequent increases in
response to Protandim. Finally, antioxidant enzymes can
also be activated independently of Nrf2 by other proteins
including p53 and sirtuins [34, 35]. However, our data show
that signiﬁcantly more cells undergo apoptosis in response
to an oxidative challenge if Nrf2 is silenced regardless of
Protandim treatment indicating the importance of Nrf2 in
cytoprotection.
We used apoptosis in endothelial cells as an outcome
because it has direct translation to vascular disease develop-
mentandoutcomes.Endothelialcellapoptosiscontributesto
plaque progression and rupture and may be an independent
riskfactorforthrombosis[36].Endothelialcellapoptosiscan
be induced by oxidized lipids as well as by ROS, and the
role of endothelial cell apoptosis in atherosclerosis has been
extensively reviewed [37–39].
4.3.TranslationandFutureStudies. Ourdatasuggestpositive
eﬀects of Protandim in healthy coronary artery endothelial8 Oxidative Medicine and Cellular Longevity
cells supporting future examination of how Protandim may
aﬀect cells that have been chronically exposed to oxidative
and lipid challenges. Most individuals experience transient
and/or chronic lipid and oxidative stress in the vasculature
throughout life, and it is the accumulated eﬀects that eventu-
ally lead to overt vascular disease. Therefore, it is of interest
to determine if Protandim can slow or reverse disease related
endothelial cell phenotypic changes using in vivo models of
chronic oxidative stress.
SupplementationwithProtandiminhumansissafe,with
no reported adverse side eﬀects [15, 16]. It has been shown
that with oral Protandim supplementation in humans,
circulating TBARs, a measure of lipid peroxidation, decrease
in 5–12 days, an eﬀect that persists with continued supple-
mentation as measured at 30 and 120 days [15]. In addition,
erythrocytes isolated from subjects who ingested Protandim
for 120 days had greater SOD and catalase activity compared
to controls [15]. The dose ingested by human subjects [15]
induces similar increases in antioxidant enzymes compared
to the 20μg/mL concentration used in our experiments.
Thus the eﬀects observed in our cell culture model directly
mirror those seen in vivo indicating that exposure of cells
to the components of Protandim in human subjects is likely
similar to what we used in vitro. Studies in vivo will need to
be performed to determine if these results are translatable to
intact coronary arteries.
5. Conclusion
Our current investigation shows for the ﬁrst time that Pro-
tandim treatment in HCAEC induces Nrf2 nuclear local-
ization, phase II antioxidant enzyme expression, and Nrf2-
dependentprotectionfromanoxidantstress.Oxidativestress
hasawell-establishedroleinCADinitiationandprogression,
and our data support further research on phytochemical
activation of Nrf2 and the endogenous antioxidant response
as a potential therapeutic approach.
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